Skip to main content

Table 2 Differences in clinical parameters in patients with or without increased physical activity

From: Influence of increased physical activity without body weight loss on hepatic inflammation in patients with nonalcoholic fatty liver disease

Parameters

Units

Baseline period

Follow-up period

P value

Patients without increased PA

 Body weight

kg

67.7 ± 3.8

68.3 ± 4.1

0.201

 Aspartic aminotransferase

IU/L

41.9 ± 3.9

37.6 ± 3.4

0.238

 Alanine transaminase

IU/L

59.2 ± 8.5

47.0 ± 5.8

0.067

 Platelets

109/L

210.6 ± 16.8

203.1 ± 16.8

0.629

 FIB-4 index

 

2.10 ± 0.28

2.24 ± 0.36

0.459

 FIB-4 index ≥ 2.67

n (%)

7 (35)

5 (25)

0.731

 γ-Glutamyltransferase

IU/L

77.4 ± 15.8

58.3 ± 9.0

0.054

 Lactate dehydrogenase

IU/L

209.6 ± 11.7

202.4 ± 8.2

0.279

 Alkaline phosphatase

IU/L

269.1 ± 20.6

269.8 ± 24.7

0.944

 Total bilirubin

mg/dL

0.66 ± 0.06

0.73 ± 0.06

0.360

 Total cholesterol

mg/dL

190.0 ± 7.6

191.8 ± 8.3

0.716

 Triglycerides

mg/dL

146.7 ± 18.1

179.3 ± 25.6

0.136

 Albumin/globulin ratio

 

1.48 ± 0.04

1.46 ± 0.04

0.526

Patients with increased PA

 Body weight

kg

69.5 ± 3.3

67.8 ± 3.3

0.104

 Aspartic aminotransferase

IU/L

61.4 ± 7.8

37.5 ± 3.0

0.004

 Alanine transaminase

IU/L

95.3 ± 10.8*

49.5 ± 5.9

< 0.001

 Platelets

109/L

227.8 ± 12.8

231.6 ± 12.8

0.584

 FIB-4 index

 

1.77 ± 0.24

1.56 ± 0.20

0.187

 FIB-4 index ≥ 2.67

n (%)

5 (20)

4 (16)

1.000

 γ-Glutamyltransferase

IU/L

89.1 ± 19.3

60.0 ± 11.5

0.015

 Lactate dehydrogenase

IU/L

201.0 ± 7.5

194.4 ± 7.6

0.188

 Alkaline phosphatase

IU/L

301.1 ± 33.6

284.9 ± 35.3

0.651

 Total bilirubin

mg/dL

1.17 ± 0.32

0.93 ± 0.11

0.373

 Total cholesterol

mg/dL

207.3 ± 9.1

205.9 ± 8.9

0.594

 Triglycerides

mg/dL

186.7 ± 25.9

166.4 ± 31.8

0.292

 Albumin/globulin ratio

 

1.35 ± 0.05

1.39 ± 0.06

0.268

  1. Data are presented as n (%) or mean ± standard error
  2. FIB-4 fibrosis-4, PA physical activity
  3. *P < 0.05, comparison between patients without increased PA and patients with increased PA during the baseline period